Blog

$Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research$

Photo of Ira Pastan from federalnewsnetwork.com

Sep 26, 2024, 11:19

Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved – NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn:

“BREAKTHROUGH IN TREATMENT: In 2012, Senior Investigator Ira Pastan, M.D., tested the immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia (HCL).

As a result, the drug is now an FDA approved therapy for the disease if it has recurred or progressed after at least two prior systemic therapies.

cancer cancer awareness Cancer research FDA fight against cancer Global fight against cancer Hairy Cell Leukemia HCL Ira Pastan NCI NCI Center for Cancer Research OncoDaily Oncology

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage